Here are Wednesday's biggest analyst calls: Nvidia, Apple, Micron, Amazon, AMD, Johnson & Johnson & more
Here are Wednesday’s biggest calls on Wall Street: Oppenheimer reiterates Nvidia as outperform Oppenheimer said it’s bullish ahead of earnings next week. “We expect NVDA CY26 FCF to approach $200B with cash return spread between buybacks and seeding emergent AI ecosystem. If half FCF used for dividend, yield would be nearly 2.5%. Reiterate Outperform, $265 target.” Daiwa reiterates Apple as outperform Daiwa raised its price target on the stock to $325 per share from $310. ” Apple’ s biggest strength is its huge ecosystem. We continue to see the shares as a core holding. 2HCY26 concerns are managing the memory situation well and the transition, which could create turbulence for 1-2 qtrs.” UBS upgrades KE Holdings to buy from neutral UBS said shares of the online China housing company platform have plenty of upside. “Since the market recovery is led by the secondary market and by tier 1 cities, we believe BEKE will be the top beneficiary due to its agency business in both the primary and the secondary market and high exposure to tier 1 cities.” Argus upgrades Wendy’s to buy from neutral Argus said buy the stock ahead of reports of the company going private. “We are upgrading our rating on Wendy’s Co . to BUY from HOLD. The shares got a big boost on May 12, with news of the potential move to take the restaurant chain private. The Financial Times reported that activist investment firm Trian Fund Management, run by Nelson Peltz, is pursuing a consortium to take Wendy’s private. Trian and its co-founders owns about 40% of the WEN stock.” Truist upgrades Sensata Technologies to buy from hold Truist said the company is firing on all cylinders. “We are upgrading ST for 4 reasons: (1) The core autos business has stabilized; (2) new management has demonstrated its ability to under promise & over-deliver; (3) Valuation of 10.9x P/E is reasonable / low for the core business and does not contemplate any outsized growth drivers, and (4) we expect ST’s growing AI/DC exposure will drive both fundamentals and valuation higher.” Bank of America reiterates Micron Technology as buy Bank of America raised its price target on the stock to $950 from $500. “Despite recent run s in memory stocks, we expect memory demand to continue outgrowing supply driven by AI, memory pricing to generally hold up (supply/demand sufficiency ratio not expected to rise above 110%), and memory (MU) ear nings to remain relatively stable through CY28.” Bank of America reiterates Nvidia as buy The bank raised its price target on the stock. “NVDA : top sector pick, raise est./PO to $320 from $300. Upcoming catalyst s include earnings, Computex tradeshow (possible new CPU launch), Vera Rubin launch, and 2H return of cash…” UBS upgrades Concept Therapeutics to buy from neutral UBS said the biotech company has plenty more room to run. “We upgrade CORT t o Buy, and raise our PT to $72 (prior Neutral/$44).” KeyBanc upgrades Zebra Technologies to overweight from sector weight KeyBanc said it sees “cost execution.” “Following ZBRA’s strong 1Q26 results, we are upgrading the shares to OW from SW with a $305 price target.” Read more. KBW initiates CoinShares at outperform KBW says the digital asset company is a “high margin platform.” “CoinShare s is a global asset management company providing investors exposure to, and facilitating the adoption of, digital assets.” Daiwa downgrades Advanced Micro Devices to outperform from buy Daiwa downgraded the stock on valuation. “Wasn’t just AMD, most semi names jumped over past 30-45 days. What changed, earnings results that overachieved and strong guidance ➢ But, we lower our rating to 2/Outp, from 1/Buy, given appreciation.” Bank of America upgrades Akamai to buy from neutral Bank of America said an “inflection is now visible” for the stock. “We upgrade Akamai to Buy and raise our PO to $175, from $130, implying 18% upside potential. The story has shifted from a legacy delivery network to a credible AI infrastructure platform. Large cloud infrastructure wins, including a $1.8bn, 7 year deal, signal real demand for distributed AI, not just narrative.” Citigroup initiates NextDecade Corp at buy Citi said the LNG company has plenty of upside. “We launch coverage of NEXT with an $11 TP and Buy rating.” William Blair upgrades Vestis to outperform from market perform The firm said in its upgrade of Vestis that the uniform company is a turnaround story. “Since new management took over almost one year ago, the company has been focused on correcting what it can control. This included pruning lower-margin business, stemming the retention decline in business it wanted to keep, and focusing aggressively on improving core operations at the branch and corporate levels.” Roth initiates Unusual Machines at buy Roth said the drone company is “well positioned.” “We expect UMAC to supply a healthy component share for DoW’s $1B Drone Dominance program. FAA Part 135 certifications are a good start in delivery, and we look for 2026 beyond-visual-line-of-sight (BVLOS) certifications. As a diversified supplier and low-cost producer, UMAC is well positioned.” Read more. Rothschild & Co Redburn initiates Heico at buy Rothschild said the company has a “proven track record.” “History teaches us tha t HEICO tends to outperform the commercial aerospace aftermarket when airline margins deteriorate, yet consensus estimates suggest otherwise.” RBC upgrades Mosaic to outperform from sector perform The firm said in its upgrade of Mosaic that it might be too early in its call but the stock too compelling to ignore. “We believe current depressed phosphate margins, due to the Strait of Hormuz closure and restricted sulphur supply, are unsustainable. Although we expect 2026 to remain volatile/uncertain due to the Iran war, and we may be early in our call, we see significant value and have strong belief that phosphate margins will eventually recover.” Citi upgrades Venture Global to buy from neutral Citi upgraded the LNG stock mainly on valuation. “We upgrade VG t o Buy and increase our TP to $17/sh from $12/sh.” Stifel downgrades Under Armour to hold from buy Stifel said it sees an “elongated turnaround.” “We are downgrading UAA shares to Hold from Buy with a $6 12-month target price. Our updated view contemplates a more challenging risk/reward profile related to 1) higher than previously anticipated SG & A expense, 2) inflection to a normalized net debt position, and 3) persistent challenges to topline growth.” Morgan Stanley reiterates Amazon as overweight Morgan Stanley said it’s bullish on Amazon’s ability to increase delivery speed. ” AMZN is expanding 30 minute delivery to 10s of millions of Americans by year-end ’26. This furthers AMZN’s surging push into the $1.7tln grocery/CPG market, is forward-looking agentic investment (infrastructure and inventory), and speaks to rising competition for DASH/UBER/CART/grocers” Guggenheim upgrades MasTec to buy from neutral Guggenheim upgraded the stock following an analyst meeting. “We are upgrading MTZ’s stock from Neutral to Buy and establishing a $480 price target. The company presented its multi-year outlook at yesterday’s analyst meeting, and we regard that outlook as reasonable or perhaps even conservative.” Compass Point upgrades OptimumBank Holdings to buy from neutral Compass Point upgraded OptimumBank f ollowing earnings. “We are raising our price target to $6.50 from $6.00, and raising our Rating to Buy from Neutral, for investors that can take a position in a company with limited float.” BTIG initiates BioAge Labs at buy BTIG said the biopharma company is well positioned. “BioAge Labs is a clinical-stage biopharmaceutical company focused on treating disease related to human aging. BioAge mines human datasets to identify proteins and genetic elements whose trajectories in early adulthood predict lifelong outcomes.” Leerink upgrades Johnson & Johnson to outperform from market perform Leerink said it sees “revenue ramps.” “We are upgradin g JNJ s hares from MP to OP and raising our PT from $252 (20.0x of our old ’27E EPS of $12.62) to $265 (21.0x of our new ’27E EPS of $12.61), representing 18% upside to Mar 12 close price of $224.” Oppenheimer upgrades Integer to outperform from market perform Oppenheimer upgraded the medical device contract development company and says it has an attractive risk/reward. “We upgrad e ITGR from Perform to Outperform with a $115 PT.”
